General Influenza Diagnostics - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242915

Publication Date:

October 1, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Influenza virus testing is not required to make a clinical diagnosis of Influenza in outpatients with suspected Influenza,Particularly during increased state-run activity when seasonal state-run influenza A and B viruses are circulating in the local community. The traditional detection methods include: RIDT, Viral Culture, DFA, Serological assays.
The global market for General Influenza Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for General Influenza Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of General Influenza Diagnostics by region & country, by Type, and by Application.
The General Influenza Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding General Influenza Diagnostics.
麻豆原创 Segmentation
By Company
F. Hoffmann-La Roche
Quidel Corporation
Thermo Fisher Scientific
Abbott Laboratories
Becton, Dickinson, and Company
DiaSorin
产颈辞惭茅谤颈别耻虫
Segment by Type:
RIDT
Viral Culture
DFA
Serological Assays
Segment by Application
Hospitals
Clinical Laboratories
Other End-User
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of General Influenza Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of General Influenza Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of General Influenza Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 General Influenza Diagnostics Product Introduction
1.2 Global General Influenza Diagnostics 麻豆原创 Size Forecast
1.3 General Influenza Diagnostics 麻豆原创 Trends & Drivers
1.3.1 General Influenza Diagnostics Industry Trends
1.3.2 General Influenza Diagnostics 麻豆原创 Drivers & Opportunity
1.3.3 General Influenza Diagnostics 麻豆原创 Challenges
1.3.4 General Influenza Diagnostics 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global General Influenza Diagnostics Players Revenue Ranking (2023)
2.2 Global General Influenza Diagnostics Revenue by Company (2019-2024)
2.3 Key Companies General Influenza Diagnostics Manufacturing Base Distribution and Headquarters
2.4 Key Companies General Influenza Diagnostics Product Offered
2.5 Key Companies Time to Begin Mass Production of General Influenza Diagnostics
2.6 General Influenza Diagnostics 麻豆原创 Competitive Analysis
2.6.1 General Influenza Diagnostics 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by General Influenza Diagnostics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in General Influenza Diagnostics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 RIDT
3.1.2 Viral Culture
3.1.3 DFA
3.1.4 Serological Assays
3.2 Global General Influenza Diagnostics Sales Value by Type
3.2.1 Global General Influenza Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global General Influenza Diagnostics Sales Value, by Type (2019-2030)
3.2.3 Global General Influenza Diagnostics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinical Laboratories
4.1.3 Other End-User
4.2 Global General Influenza Diagnostics Sales Value by Application
4.2.1 Global General Influenza Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global General Influenza Diagnostics Sales Value, by Application (2019-2030)
4.2.3 Global General Influenza Diagnostics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global General Influenza Diagnostics Sales Value by Region
5.1.1 Global General Influenza Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global General Influenza Diagnostics Sales Value by Region (2019-2024)
5.1.3 Global General Influenza Diagnostics Sales Value by Region (2025-2030)
5.1.4 Global General Influenza Diagnostics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America General Influenza Diagnostics Sales Value, 2019-2030
5.2.2 North America General Influenza Diagnostics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe General Influenza Diagnostics Sales Value, 2019-2030
5.3.2 Europe General Influenza Diagnostics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific General Influenza Diagnostics Sales Value, 2019-2030
5.4.2 Asia Pacific General Influenza Diagnostics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America General Influenza Diagnostics Sales Value, 2019-2030
5.5.2 South America General Influenza Diagnostics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa General Influenza Diagnostics Sales Value, 2019-2030
5.6.2 Middle East & Africa General Influenza Diagnostics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions General Influenza Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions General Influenza Diagnostics Sales Value
6.3 United States
6.3.1 United States General Influenza Diagnostics Sales Value, 2019-2030
6.3.2 United States General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe General Influenza Diagnostics Sales Value, 2019-2030
6.4.2 Europe General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China General Influenza Diagnostics Sales Value, 2019-2030
6.5.2 China General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.5.3 China General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan General Influenza Diagnostics Sales Value, 2019-2030
6.6.2 Japan General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea General Influenza Diagnostics Sales Value, 2019-2030
6.7.2 South Korea General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia General Influenza Diagnostics Sales Value, 2019-2030
6.8.2 Southeast Asia General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India General Influenza Diagnostics Sales Value, 2019-2030
6.9.2 India General Influenza Diagnostics Sales Value by Type (%), 2023 VS 2030
6.9.3 India General Influenza Diagnostics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 F. Hoffmann-La Roche
7.1.1 F. Hoffmann-La Roche Profile
7.1.2 F. Hoffmann-La Roche Main Business
7.1.3 F. Hoffmann-La Roche General Influenza Diagnostics Products, Services and Solutions
7.1.4 F. Hoffmann-La Roche General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.1.5 F. Hoffmann-La Roche Recent Developments
7.2 Quidel Corporation
7.2.1 Quidel Corporation Profile
7.2.2 Quidel Corporation Main Business
7.2.3 Quidel Corporation General Influenza Diagnostics Products, Services and Solutions
7.2.4 Quidel Corporation General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.2.5 Quidel Corporation Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific General Influenza Diagnostics Products, Services and Solutions
7.3.4 Thermo Fisher Scientific General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.3.5 Abbott Laboratories Recent Developments
7.4 Abbott Laboratories
7.4.1 Abbott Laboratories Profile
7.4.2 Abbott Laboratories Main Business
7.4.3 Abbott Laboratories General Influenza Diagnostics Products, Services and Solutions
7.4.4 Abbott Laboratories General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.4.5 Abbott Laboratories Recent Developments
7.5 Becton, Dickinson, and Company
7.5.1 Becton, Dickinson, and Company Profile
7.5.2 Becton, Dickinson, and Company Main Business
7.5.3 Becton, Dickinson, and Company General Influenza Diagnostics Products, Services and Solutions
7.5.4 Becton, Dickinson, and Company General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.5.5 Becton, Dickinson, and Company Recent Developments
7.6 DiaSorin
7.6.1 DiaSorin Profile
7.6.2 DiaSorin Main Business
7.6.3 DiaSorin General Influenza Diagnostics Products, Services and Solutions
7.6.4 DiaSorin General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.6.5 DiaSorin Recent Developments
7.7 产颈辞惭茅谤颈别耻虫
7.7.1 产颈辞惭茅谤颈别耻虫 Profile
7.7.2 产颈辞惭茅谤颈别耻虫 Main Business
7.7.3 产颈辞惭茅谤颈别耻虫 General Influenza Diagnostics Products, Services and Solutions
7.7.4 产颈辞惭茅谤颈别耻虫 General Influenza Diagnostics Revenue (US$ Million) & (2019-2024)
7.7.5 产颈辞惭茅谤颈别耻虫 Recent Developments
8 Industry Chain Analysis
8.1 General Influenza Diagnostics Industrial Chain
8.2 General Influenza Diagnostics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 General Influenza Diagnostics Sales Model
8.5.2 Sales Channel
8.5.3 General Influenza Diagnostics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

F. Hoffmann-La Roche
Quidel Corporation
Thermo Fisher Scientific
Abbott Laboratories
Becton, Dickinson, and Company
DiaSorin
产颈辞惭茅谤颈别耻虫

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.